May 20, 2026 · 7 min read

Biosimilar technology transfer, step by step

Moving a biosimilar onto your site is less about the recipe and more about reproducing a process. A practical map of a biologics tech transfer, from gap assessment to PPQ.


A biosimilar technology transfer is not handing over a document and a cell bank. Because a biologic's identity is defined by its process, the goal of the transfer is to reproduce a process closely enough that the product's critical quality attributes stay within the same ranges. Here is how a well-run transfer is sequenced.

1. Gap assessment

Before anything moves, both sides map the sending process against the receiving site's equipment, utilities, analytical capability and quality systems. The output is a gap list that drives the whole plan: a different bioreactor scale, a chromatography skid that behaves differently, an assay the receiving QC lab has never run.

2. Documentation and materials transfer

The cell bank, the process description, raw-material specifications, and the analytical methods move under a transfer protocol. Raw materials matter more than teams expect: a change in resin lot, media supplier or single-use bag can shift the product. Qualify materials early.

3. Analytical method transfer

The receiving lab must demonstrate it can run the release and characterization methods and get equivalent results. This usually runs in parallel with, and slightly ahead of, the process work, because you cannot judge an engineering run without trustworthy assays.

4. Engineering runs

Non-GMP engineering runs shake out the process at the receiving scale: mixing, aeration, hold times, column loading. Expect to adjust. The exit criterion is a process that reproducibly lands the critical quality attributes in range.

5. Process performance qualification (PPQ)

Consecutive GMP conformance batches demonstrate the transferred process is under control at commercial scale. PPQ data, plus a comparability exercise against the reference material, underpins the regulatory submission.

What derails transfers

  • Underestimating analytical transfer: the process cannot move faster than the assays that judge it.
  • Raw-material and single-use changes treated as trivial.
  • Scale differences between sending and receiving bioreactors.
  • Comparability planned as an afterthought rather than designed in from the gap assessment.

BOOKPHARM supports biosimilar technology transfer and drug-substance supply across a range of monoclonal antibodies and insulins. If you are planning a transfer onto your site, we can help scope the gap assessment and the comparability strategy.